Results 81 to 90 of about 128,389 (322)

Immunocytochemical study of BCR and bcr-abl localization in K562 cells [PDF]

, 2010
Aim: To obtain polyclonal antibodies against recombinant proteins recognizing Bcr domain and fusion region of Bcr-Abl and analyze the patterns of intracellular distribution of Bcr and Bcr-Abl proteins in K562 cells of chronic myelogenous leukemia ...
Dubrovska, A.N., Dybkov, M.V., Gluzman, D.F., Maliuta, S.S., Nadgorna, V.A., Telegeev, G.D., Zavelevich, M.P.   +6 more
core  

Recent progress on nanotechnologies for enhancing blood‐brain barrier permeability

Smart Molecules, EarlyView.
In this review, we summarize innovative strategies for harnessing the power of nanotechnology to enhance blood‐brain barrier permeability, a key challenge for central nervous system (CNS) drug delivery. We overview structural innovation of nanocarriers, improvements in targeting strategies, and nanotechnology‐enhanced brain imaging.
Qibin Liu, Zhuoqian Chen, Anthony Guiseppi‐Elie, Fanling Meng, Liang Luo   +4 more
wiley   +1 more source

The FABD domain is critical for the oncogenicity of BCR/ABL in chronic myeloid leukaemia

Cell Communication and Signaling
Background Abnormally expressed BCR/ABL protein serves as the basis for the development of chronic myeloid leukaemia (CML). The F-actin binding domain (FABD), which is a crucial region of the BCR/ABL fusion protein, is also located at the carboxyl end of
Renren Zheng, Wei Wei, Suotian Liu, Dachuan Zeng, Zesong Yang, Jie Tang, Jinfeng Tan, Zhenglan Huang, Miao Gao   +8 more
doaj   +1 more source

BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia [PDF]

, 2012
MECOM oncogene expression correlates with chronic myeloid leukaemia (CML) progression. Here we show that the knockdown of MECOM (E) and MECOM (ME) isoforms reduces cell division at low cell density, inhibits colony-forming cells by 34% and moderately ...
Alzuherri, Aytekin, Barjesteh van Waalwijk van Doorn-Khosrovani, Bartholomew, Ben-Neriah, Bianchini, Carapeti, Carlesso, Daghistani, De Weer, Elrick, Fabbro, Fears, Gerhardt, Goyama, Hamilton, Henzan, Hoyt, Huang, Håkansson, Irvine, Jørgensen, Khanna-Gupta, Kilbey, Konopka, Kurzrock, Kustikova, Lin, Livak, Lugthart, Lugthart, Melo, Mitani, Morishita, Morishita, Morishita, Morishita, Nakamura, Nunoda, O'Hare, Ogawa, Paquette, Pendergast, Russell, Sellers, Skorski, Smith, Stevens-Kroef, Suzukawa, Valent, Wetzler, Wieser, Wimmer, Yuasa   +53 more
core   +1 more source

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Journal of Clinical Investigation, 2011
Imatinib therapy, which targets the oncogene product BCR-ABL, has transformed chronic myeloid leukemia (CML) from a life-threatening disease into a chronic condition.
A. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. Deininger, B. Druker   +5 more
semanticscholar   +1 more source

Imatinib decreases germ cell survival and germline stem cell proliferation in rodent testis ex vivo and in vitro

Andrology, EarlyView.
Abstract Background Imatinib and dasatinib are tyrosine kinase inhibitors (TKIs) increasingly used to treat several diseases in both children and adults at fertile age. We have previously shown that imatinib has adverse effects on developing testis, and imatinib‐treated male patients have been reported to have reduced sperm counts.
Anna Eggert, Sini Laasanen, Mirja Nurmio, Aida Wahlgren, Kirsi Jahnukainen, Kim Eerola, Miisael Nieminen, Opeyemi Olotu, Noora Kotaja, Juho‐Antti Mäkelä, Jorma Toppari   +10 more
wiley   +1 more source

Kill Two Birds with One Stone: A Multifunctional Dual‐Targeting Protein Drug to Overcome Imatinib Resistance in Philadelphia Chromosome‐Positive Leukemia

Advanced Science, 2022
The Bcr/Abl plays a central role in Philadelphia chromosome‐positive (Ph+) leukemia because of the constitutively activated Abl tyrosine kinase and its downstream pathways.
Bohan Ma, Hui Feng, Chao Feng, Yi Liu, Hailing Zhang, Jincheng Wang, Wenjuan Wang, Pengcheng He, Fan Niu   +8 more
doaj   +1 more source

Uptake of synthetic low density lipoprotein by leukemic stem cells — a potential stem cell targeted drug delivery strategy [PDF]

, 2010
Chronic Myeloid Leukemia (CML) stem/progenitor cells, which over-express Bcr-Abl, respond to imatinib by a reversible block in proliferation without significant apoptosis.
Alison M. Michie, Baillie, Bellodi, Bhatia, Bocchia, Brown, Claire Crossan, Collins, Copland, Davies, Deckelbaum, Dirks, Firestone, Gal, Gavin W. Halbert, Ghalaut, Graham, Halbert, Hamilton, Hamilton, Hatziieremia, Hayavi, Hayavi, Heather G. Jørgensen, Ho, Hochhaus, Holyoake, Hughes, Jordanides, Jorgensen, Jorgensen, Kramer, Linda Scobie, Moira A. Elliott, Nikanjam, Nikanjam, Owens, Peixun Zhou, Rousselot, Sophia Hatziieremia, Stingl, Tatidis, Tessa L. Holyoake, Vitols, Weisberg, White, White, WilsonRawls   +47 more
core   +1 more source

Concomitant occurrence of BCR-ABL and JAK2V617F mutation [PDF]

Blood, 2011
To the editor: In a recent issue of the journal, Makishima et al[1][1] reported on the occurrence of mutations typically associated with Philadelphia-chromosome (Ph1) negative myeloproliferative (MPN)/ myelodysplastic neoplasms in 54 patients with typical chronic myelogenous leukemia (CML ...
PIERI, LISA, SPOLVERINI, AMBRA, SCAPPINI, BARBARA, U. Occhini, S. Birtolo, BOSI, ALBERTO, F. Albano, C. Fava, VANNUCCHI, ALESSANDRO MARIA   +8 more
openaire   +6 more sources

Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Therapy for Rectal Cancer: Cost Analysis in a Public Healthcare System

ANZ Journal of Surgery, EarlyView.
Costs of neoadjuvant therapy. ABSTRACT Purpose Total neoadjuvant therapy (TNT) has become the standard of care in locally advanced rectal cancer, but its economic impact is unclear. This study compares the cost of TNT with conventional neoadjuvant therapy (CNT), consisting of either short‐course radiotherapy or long‐course chemoradiotherapy, within a ...
Ishraq Murshed, Sergei Bedrikovetski, Ishmam Murshed, Zachary Bunjo, Tracy Fitzsimmons, Michelle Thomas, Tarik Sammour   +6 more
wiley   +1 more source